Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.70 |
| ▸ | PTK2 | Q05397 | 19/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16192753 | 1.00 | LRRK2 (0.70) | LRRK2PTK2 | |
| SCHEMBL16192754 | 1.00 | LRRK2 (0.70) | LRRK2PTK2 | |
| SCHEMBL12562360 | 0.94 | LRRK2 (0.61) | LRRK2PTK2 | |
| SCHEMBL12562743 | 0.94 | LRRK2 (0.61) | LRRK2PTK2 | |
| SCHEMBL12562357 | 0.94 | LRRK2 (0.61) | LRRK2PTK2 | |
| SCHEMBL16200473 | 0.94 | LRRK2 (0.68) | LRRK2PTK2 | |
| SCHEMBL12562355 | 0.92 | PTK2 (0.60) | LRRK2PTK2 | |
| SCHEMBL12563008 | 0.92 | LRRK2 (0.68) | LRRK2PTK2 | |
| SCHEMBL12562882 | 0.91 | PTK2 (0.59) | LRRK2PTK2 | |
| SCHEMBL1943771 | 0.91 | LRRK2 (0.66) | LRRK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435411-B1 | 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2435411-B1 | 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8410126-B2 | Pyrimidine inhibitors of PKTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2010136559-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | RB1, MKI67, CCNA1 | LRRK2 2645/4885PTK2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.